Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Madhuchanda Kar

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of the Indian Medical Association|February 24, 2006
Oncology--its relevance in a developing country like oursMadhuchanda Kar
Journal of the Indian Medical Association|January 30, 2004
Ageing and healthSukumar Mukherjee, Madhuchanda Kar
Genetic Testing and Molecular Biomarkers|March 8, 2011
A novel polymorphism in codon 25 of the KRAS gene associated with gallbladder carcinoma patients of the eastern part of IndiaVishmadeb Pramanik, Biswanath N Sarkar, Madhuchanda Kar, et al.
Oncotargets and Therapy|June 27, 2014
Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II studyK Govind Babu, Kumar Prabhash, Ashok K Vaid, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of the Indian Medical Association|February 24, 2006
Oncology--its relevance in a developing country like oursMadhuchanda Kar
Journal of the Indian Medical Association|January 30, 2004
Ageing and healthSukumar Mukherjee, Madhuchanda Kar
Genetic Testing and Molecular Biomarkers|March 8, 2011
A novel polymorphism in codon 25 of the KRAS gene associated with gallbladder carcinoma patients of the eastern part of IndiaVishmadeb Pramanik, Biswanath N Sarkar, Madhuchanda Kar, et al.
Oncotargets and Therapy|June 27, 2014
Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II studyK Govind Babu, Kumar Prabhash, Ashok K Vaid, et al.
Pageof 1